The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing amitriptyline, amitriptyline/amitriptylinoxide, and amitriptylinoxide, made the following conclusions.
In view of the available data on the interaction with duloxetine, intoxication in children and Brugada syndrome, the PRAC considers that a causal relationship between the use of medicinal products containing amitriptyline, amitriptyline/amitriptylinoxide, amitriptylinoxide and the occurrence of these risks is at least possible. The PRAC concluded that appropriate changes must be made to the instructions for medical use.
The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) agrees with the PRAC scientific conclusions.
CMDh considers that the benefit/risk balance of medicinal products containing amitriptyline, amitriptyline/amitriptylinoxide, and amitriptylinoxide remains unchanged, taking into account the proposed changes to the instructions for medical use.
Amendments to be included in the relevant sections of the package insert (new text underlined in bold, deleted text struck through).
Section “Interaction with other medicinal products and other forms of interaction”
Interaction with duloxetine
CYP2D6 inhibitors: the isoenzyme CYP2D6 may be inhibited by many medicinal products, for example antipsychotics, serotonin reuptake inhibitors, β-adrenergic receptor blockers, and antiarrhythmic agents. Examples of strong CYP2D6 inhibitors are bupropion, fluoxetine, paroxetine, and quinidine. These medicinal products can lead to a substantial reduction in metabolism and a marked increase in plasma TCA concentrations. Plasma TCA concentrations should be monitored when TCA is administered together with another medicinal product known to be a strong inhibitor of CYP2D6. The dose of amitriptyline must be determined (see the section “Method of administration and doses”). Caution is recommended when amitriptyline is used concomitantly with duloxetine, a moderate inhibitor of CYP2D6.
“Overdose” section
Intoxication in children
Overdose in children can have serious consequences. Children are particularly prone to developing coma, cardiotoxicity, respiratory depression, seizures, hyponatremia, lethargy, sinus tachycardia, drowsiness, nausea, vomiting, and hyperglycemia.
Brugada syndrome
Cardiac symptoms: arrhythmias (ventricular tachyarrhythmias, flutter-fibrillation, ventricular fibrillation). The ECG typically shows a prolonged PR interval, widened QRS complex, prolonged QT, widened or inverted T wave, ST segment depression, as well as heart block of varying degrees up to cardiac arrest. QRS widening usually correlates clearly with the severity of toxicity after an acute overdose. Heart failure, arterial hypotension and cardiogenic shock develop. Metabolic acidosis and hypokalemia increase. Post-marketing studies and the literature contain data on cases of unmasking of Brugada syndrome and a Brugada ECG pattern in amitriptyline overdose.
Перелік лікарських засобів, що містять амітриптилін (amitriptyline) і дозволені до медичного застосування в Україні (за даними Державного реєстру лікарських засобів України станом на 05.11.2021).
To analyze the published information, the applicant must use the original text available at the link https://www.ema.europa.eu/en/documents/psusa/amitriptyline-amitriptyline/amitriptylinoxide-amitriptylinoxide-cmdh-scientific-conclusions-grounds-variation-amendments-product/00010374/202101_en.pdf